Navigation Links
Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer

GSK Announces Launch of Largest Ever Phase III Clinical Trial in Lung Cancer Treatment

PHILADELPHIA, June 05, 2007 /PRNewswire-FirstCall/ -- GlaxoSmithKline today announced final results of a Phase II proof-of-concept clinical trial of its investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) in MAGE-A3 positive patients with stage IB or II Non-Small Cell Lung Cancer (NSCLC). These data were presented at the 2007 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, [Abstract No: 7554]. Final trial analysis showed a 27% reduction in the relative risk of cancer recurrence following surgery in patients treated with the MAGE-A3 ASCI, compared to placebo.

"Final results from this trial confirm the positive interim results released last year at ASCO 2006, and support expanded testing of this novel cancer immunotherapy," said Paul A. Bunn Jr., M.D., James Dudley Endowed Professor of Oncology, Professor of Medicine and Director of the University of Colorado Cancer Center, Aurora, Colorado. "This approach represents a potentially momentous shift in the cancer treatment paradigm. I believe we have only just scratched the surface of what is possible and look forward to seeing the results of the Phase III trial in due course."

Based on these encouraging data, GSK also announced today the opening of patient recruitment to the randomized and controlled Phase III efficacy and safety trial for this novel cancer immunotherapy; the largest clinical trial ever conducted in lung cancer treatment. MAGE-A3 ASCI will be evaluated as adjuvant therapy in about 2,270 MAGE-A3 positive patients with completely resected stage IB, II or IIIA NSCLC.

GSK's ASCIs aim to stimulate the patient's own immune response to identify and attack cancer cells in a highly specific manner. This novel cancer immunotherapy is developed using tumor specific antigens, delivered as highly puri
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
2. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
3. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
4. Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
5. Genetic Analysis Systems Enter the Clinical Mainstream
6. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
7. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
8. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
(Date:12/24/2014)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... preliminary financial results for the first quarter of ... Ended September 30, 2014 Financial Highlights: , ... in 1Q14 with gross margins improved to 52% ...
(Date:12/24/2014)... 24, 2014  Conkwest, Inc., the Natural Killer ... Natural Killer (NK) cell-line platform, Neukoplast® (NK-92™) as ... Soon-Shiong , NantWorks founder, physician scientist and biotechnology ... purchase approximately $48 million of the Company,s Class ... he will be named Co-Chairman of the Conkwest ...
(Date:12/24/2014)... , Dec. 23, 2014 PuraMed BioScience®, ... of over-the-counter (OTC) medicinal and healthcare products, announced it ... MigraPure® H, a hemp-based, advanced headache relief product, for ... in Colorado , Washington ... With the MigraPure H Advanced headache relief ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... a clinical-stage company focused on commercialization of novel ... restatement of its exclusive international license agreement with ... technology related to monitoring drug therapy compliance.  The ... Sequella and UMB, addresses transdermal detection of a ...
... , a leading provider of therapeutic drug monitoring and ... today the appointment of David Cohen to Chief Operating ... responsible for new business analysis and development to expand ... Millennium,s legislative initiatives and community outreach programs. ...
Cached Medicine Technology:Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology 2Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology 3Millennium Laboratories Announces New Chief Operating Officer David Cohen 2
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- Researchers say they ... that develop into eggs and sperm. While this ... is the first time that these types of cells ... efficiently using human stem cells, according to the team ... creation of primordial germ cells is one of the ...
(Date:12/24/2014)... ladies, new fashionable outfits are necessary when heading into a ... Angeldress.co.uk has chosen some of their best dresses ... by launching a promotion on its cheap clothes and fashion ... off, like a cheap suit. , “All items are in ... are among the hottest items in the global market. They ...
(Date:12/24/2014)... Lauderdale, FL (PRWEB) December 24, 2014 There’s ... these days. With the Republican Party now in control of ... begins again for the Affordable Care Act. A lawsuit has ... that delays of certain provisions in the ACA have resulted ... (1) Also, a Supreme Court hearing will take place to ...
(Date:12/24/2014)... St. Louis, MO (PRWEB) December 24, 2014 ... Onder Law Firm announce an update to their website, ... information explains the difference between talcum powder class action ... provide weekly talcum powder and ovarian cancer updates at ... , “Talcum powder lawsuits for ovarian cancer claims are ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 ... hurt your child in the classroom, a new study finds. ... lagged behind by eighth grade, said researchers who reviewed questionnaires ... "The largest effects were found for the kids who reported ... assistant professor of human sciences at Ohio State University. "On ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Starts Its Big Sales by Offering Various Kinds of Cheap Clothes and Fashion Accessories 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 4Health News:Can Fast Food Hinder Learning in Kids? 2
... W. M. Keck Foundation has awarded Arizona State University ... scientists led by Deirdre Meldrum, Ph.D., at the Biodesign ... three-dimensional (3D) imaging microscope, called a "Cell-CT" scanner, that ... living cells. This groundbreaking technology will allow researchers to ...
... help explain why African-Americans are twice as likely to be ... new study by Johns Hopkins researchers. The findings, if ... as easy as taking a cheap potassium supplement. ... taking potassium supplements," says Hsin-Chieh "Jessica" Yeh, Ph.D., an assistant ...
... , WEDNESDAY, March 2 (HealthDay News) -- Countering ... from mental illness, a new report says there,s actually no ... they often go without treatment that could prevent them from ... "pervasive, but mistaken, impression that young children do not develop ...
... HealthDay Reporter , TUESDAY, March 1 (HealthDay News) ... to increase the risk for breast cancer among postmenopausal ... found little or no connection between breast cancer and ... may be surfacing for the first time, experts noted. ...
... 18th Conference on Retroviruses and Opportunistic Infections is ... from February 27 through March 2. Day three of ... presentations from scientists supported by the National Institute of ... Institutes of Health. iPrEx Update , ...
... , Emory University experts predict that rates of depressive disorders ... In an editorial published in the March, 2011 issue of ... author Boadie Dunlop, MD, writes "Compared to women, many men ... protectors of their families. Failure to fulfill the role of ...
Cached Medicine News:Health News:$1 million from W.M. Keck Foundation spurs development of new generation 3-D 'Cell-CT' imaging 2Health News:$1 million from W.M. Keck Foundation spurs development of new generation 3-D 'Cell-CT' imaging 3Health News:Potassium levels possible key to racial disparity in Type 2 diabetes 2Health News:Even Tiny Tots May Develop Mental Health Problems 2Health News:Study Finds Smoking Linked to Breast Cancer Risk 2Health News:Study Finds Smoking Linked to Breast Cancer Risk 3Health News:CROI -- Day 3: Selected highlights of NIH-supported research 2Health News:Depressing future for men? 2
... (E3) is one of the 3 major ... and estrone). In terms of estrogenic activity, ... [1]. Estriol is produced almost exclusively during ... in the normal human fetus. During pregnancy, ...
Assay uses highly specific rabbit anti-estriol antibody reparation - negligible cross-reactivity with other estrogen metabolites. Excellent assay precision and reproducibility. Superior sensitivity ...
... (E1) is one of the three major ... and estriol. Estrone is produced primarily from ... or gonads [1,2]. In premenopausal adult women, ... by the ovary. In prepubertal children, men ...
... most abundant circulating estrogen in non-pregnant women ... Sulfate is a major metabolite of estradiol ... in blood [2,3]. In premenopausal women, estrone ... and estradiol, rising gradually during the follicular ...
Medicine Products: